Imprimis Recalls Dexamethasone-Moxifloxacin Injection Due to Sterility Concerns
Imprimis NJOF, LLC is recalling 6,520 vials of Dexamethasone-Moxifloxacin PF Injection because 13 vials were found with faulty crimps, raising concerns about sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score (4) according to the rubric, particularly given the risk of infection from a lack of sterility assurance in an injectable drug.
Plain-English summary
Imprimis NJOF, LLC is recalling 6,520 vials of Dexamethasone-Moxifloxacin PF Injection (1/5) mg/mL. The recall is due to a lack of assurance of sterility, as 13 vials were discovered to have faulty crimps.
The affected product is identified by Lot # 20JUN010 and has an expiration date of 5/12/21. The recall covers distribution nationwide in the U.S.A.
Consumers and healthcare providers should stop using the affected product and contact Imprimis NJOF, LLC at (844) 446-6979 for further instructions.
The recalled product
- Product
- Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979
- Manufacturer
- Imprimis NJOF, LLC
- Category
- Drug — Injectable
- Affected units
- 6,520
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 20JUN010
- Exp 5/12/21
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Imprimis NJOF, LLC
See all →- HighTri-Moxi intraocular injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighIntraocular injection syringes recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighDexamethasone and moxifloxacin injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- ModerateCyclosporine eye drops recalled as subpotent across many compounded lots
FDA (Drugs) · 2025-11-26
- ModerateCompounded quadruple ophthalmic solution returned subpotent assay results in stability testing
FDA (Drugs) · 2025-07-30
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29